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BACKGROUND: Disabled phosphatidylinositol 3-kinase (PI3K)/AKT and mitogen-activated protein kinase/extracellular signal-regulated
kinase signalling is involved in endometrial carcinogenesis, and there is evidence that expression of epidermal growth factor receptor
(EGFR) family members has a role in such intracellular signalling pathways. This study analysed the prognostic impact of EGFR family
expression in endometrial cancer in relation to PI3K–AKT and MAPK–ERK signalling, as well as drug sensitivity.
METHODS AND RESULTS: Immunohistochemical analysis using 63 surgical specimens of endometrioid-type endometrial cancers revealed
that EGFR, human epidermal growth factor receptor (HER)-2 and HER-4 were expressed in 25 (39.7%) of 63, 26 (41.3%) of 63 and
31 (49.2%) of 63 tumours, respectively. Gene amplification of HER-2 was observed in 2 of 26 patients with high HER-2 expression.
Kaplan–Meier analysis revealed that high HER-2 expression was a factor that negatively influenced the progression-free and overall
survival rate (Po0.05), and multivariate analysis showed high HER-2 expression to be an independent prognostic factor.
Subsequently, we performed in vitro knockdown analysis to investigate the linkage between HER-2 expression and PI3K–AKT
pathways. Short interfering RNA (siRNA)-based knockdown of HER-2 in endometrial cancer cells led to a significant reduction in
phosphorylated AKT (p-AKT) expression, indicating the existence of a HER-2/PI3K-AKT axis. As the PI3K–AKT pathway is known to
have crucial roles in anticancer drug sensitivity, we examined the involvement of HER-2 in sensitivity to paclitaxel. Short interfering
RNA-based knockdown of HER-2 conferred increased sensitivity to paclitaxel in endometrial cancer cells, attenuating the induction of
p-AKT on paclitaxel stimulation, which was cancelled by inactivating AKT by the introduction of a dominant-negative form.
CONCLUSION: HER-2 is a significant prognostic factor of endometrioid-type endometrial cancer, as well as a key molecule that affects
paclitaxel sensitivity by HER-2 interaction with the PI3K–AKT pathway.
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Endometrial cancer is the second most common gynaecological
malignancy in Japan, and its incidence in Japan has increased
dramatically over the last decade. Although premalignant lesions
of endometrial cancer have been well characterised, the molecular
pathways of endometrial carcinogenesis remain unclear. Previous
studies have identified various genetic mutations in endometrial
cancer, including PTEN, PIK3CA and KRAS. The PTEN mutation is
the most common genetic abnormality detected in endometrioid-
type endometrial cancer (Tashiro et al, 1997; Mutter et al, 2000;
Kanaya et al, 2005). The fundamental in vivo role of PTEN is to
inhibit the phosphatidylinositol 3-kinase (PI3K)–AKT pathway.
Mutation of PTEN can disable this inhibitory function, inducing
the antiapoptotic pathway. Recently, mutation of a novel
oncogene, PIK3CA, was discovered in multiple human epithelial
cancers, including endometrial carcinoma (Oda et al, 2005; Hayes
et al, 2006; Velasco et al, 2006); this oncogene encodes the catalytic
p110a subunit of PI3K in various cancers (Samuels et al, 2004).
The mutant proteins have been shown to display enhanced lipid-
kinase activity. These findings show the critical roles that the
PI3K–AKT pathway has in endometrial carcinogenesis. Another
prevalent genetic abnormality in endometrial carcinogenesis is
mutation of the KRAS gene (Mizuuchi et al, 1992; Enomoto et al,
1993). The extracellular signal-regulated kinase–mitogen-activated
protein kinase (ERK–MAPK) pathway is activated by mitogenic
stimuli mediated by receptor-type tyrosine kinases and G-protein-
coupled receptors, leading to sequential phosphorylation of RAS,
RAF, MEK and ERK1/2. Phosphorylated ERK translocates to the
nucleus and regulates a range of substrates that promote cell
proliferation, motility, differentiation and survival (Marshall, 1999;
Chang and Karin, 2001; Shaw and Cantley, 2006). A KRAS
mutation can lead to continuous stimulation of its downstream
targets, resulting in ERK1/2 activation in the absence of mitogenic
stimuli. Thus, most of these prevalent genetic alterations observed
in endometrial cancer stimulate the PI3K–AKT and MAPK–ERK
pathways, which may have major roles in endometrial carcino-
genesis. However, the upstream pathways for their activation
remain unclear.
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epidermal growth factor receptor (HER)-1), HER-2, HER-3 and
HER-4, which share structural homology consisting of an
extracellular domain and a cytoplasmic signal-transduction
domain with tyrosine kinase activity (Olayioye et al, 2000). Many
kinds of tumour cells express multiple EGFR members, which
interact to form an array of homodimers and heterodimers.
Human epidermal growth factor receptor-2 is predominantly
activated by forming a heterodimer with other EGFR members,
rather than forming a homodimer (Goldman et al, 1990; Wada
et al, 1990; Gamett et al, 1995). Heterodimerisation of HER-2 can
result in the activation of intracellular signalling cascades, such as
the PI3K–AKT and MAPK–ERK pathways (Dougall et al, 1994;
Olayioye et al, 2000; Olayioye, 2001; Asanuma et al, 2005).
However, the roles of the EGFR family in endometrial cancer
have not been well investigated, particularly in relation to the
PI3K–AKT and MAPK–ERK pathways.
In this study, we examined the status of expression of EGFR
family members and their involvement in the PI3K–AKT and
MAPK–ERK pathways in endometrial cancer. Furthermore, the
role of the EGFR family in patient survival and paclitaxel
sensitivity was investigated.
MATERIALS AND METHODS
Patients and tissue samples
A total of 63 patients with endometrioid-type endometrial cancer
(mean age, 57.5 years; range, 32–78 years) treated at the
Department of Obstetrics and Gynecology, Kanazawa University
Hospital, from January 1995 to December 2002, were enrolled in
the study. All patients underwent a total abdominal or radical
hysterectomy plus bilateral salpingo-oophorectomy. Systemic
retroperitoneal lymphadenectomy was performed in approxi-
mately 70% of patients. Staging was performed for all patients
using the International Federation of Gynaecology and Obstetrics
(FIGO) surgical staging system: 46 tumours were classified as stage I
(substages: Ia, 10 tumours; Ib, 28 tumours; and Ic, eight tumours);
six tumours were classified as stage II (substages: IIa, three
tumours and IIb, three tumours); nine tumours were classified as
stage III (substages: IIIa, three tumours and IIIc, six tumours); and
two tumours were classified as stage IV. On the basis of
histological examination, 34 tumours were classified as grade
(G)1, 14 tumours were classified as G2 and 15 tumours were
classified as G3. Patients with deep myometrial invasion, cervical
involvement and special histology underwent external radio-
therapy, whereas those with positive peritoneal cytology or
retroperitoneal lymph-node metastasis were treated with 4–6
cycles of CAP chemotherapy (90mgm
 2 cisplatin, 50mgm
 2
doxorubicin and 500mgm
 2 cyclophosphamide) or TC chemo-
therapy (180mgm
 2 paclitaxel, and carboplatin, according to
Chatelut’s formula (area under the curve¼5mgml
 1min
 1)) as
postoperative adjuvant therapy. Patient treatment was followed up
with a gynaecological examination, recording of laboratory data,
transvaginal and abdominopelvic ultrasonography and a radio-
logical examination. Data from regular follow-up visits to the
outpatient department were stored in a database designed
specifically for endometrial carcinoma patients. A telephone survey
to update the status of all surviving patients was carried out in
August 2006. The exact date of disease recurrence was defined as the
date when apparent tumours were detected by ultrasonographic or
radiological examinations. Tumour samples were collected at the
time of surgery, with written informed consent from patients and
approval of the Ethics Committee of Kanazawa University. Half of
each tissue sample was examined histologically by pathologists, and
the remaining portion of each sample was frozen at  801Cu n t i l
DNA extraction for mutation analysis.
Mutation analysis
Of the 63 endometrial cancers, 45 were available for DNA
sequencing and had been evaluated previously for mutations in
PTEN, PIK3CA and KRAS (Kanaya et al, 2005; Mizumoto et al,
2007; Mori et al, 2007). All exons of the PTEN gene, exons 9 and 20
of the PIK3CA gene and exon 1 of the KRAS gene (including
codons 12 and 13) were amplified by polymerase chain reaction
(PCR) using primer sets described previously (Kanaya et al,
2005; Mizumoto et al, 2007; Mori et al, 2007). Polymerase chain
reaction products were purified using the Qiagen PCR purification
kit (Qiagen, Valencia, CA, USA), and direct sequencing was
performed. Polymerase chain reaction products with suspected
mutations were reamplified and subsequently cloned into the
pGEM-T Easy vector (Promega, Mannheim, Germany), and
sequencing was performed using at least three clones.
Immunohistochemistry
Immunohistochemical analysis was performed using formalin-
fixed, paraffin-embedded specimens from the 63 endometrioid-
type endometrial cancer samples with a rabbit polyclonal antibody
to HER-2 (code number A0485) (DakoCytomation, Carpinteria,
CA, USA), a mouse monoclonal antibody to EGFR (clone
EGFR.113) (Novocastra, Newcastle upon Tyne, UK) and a rabbit
monoclonal antibody to HER-4 (No. 4792; Cell Signaling
Technology, Beverly, MA, USA). Of these, 39 cancers had been
evaluated previously using mouse monoclonal antibody to
MLH1 (clone G168-15, code 13271A) (PharMingen, San Diego,
CA, USA) (Kanaya et al, 2005). After the specimens were
deparaffinised in xylene and a graded alcohol series, epitope
retrieval was performed. The sections were heated in a microwave
oven at 700W for 10min in 1  antigen retrieval solution
(Biogenex, San Ramon, CA, USA). Endogenous peroxidase was
then blocked by immersing the sections in 0.3% H2O2–methanol
for 30min. After blocking with horse serum, the primary
antibodies were diluted at 1:20 (for EGFR) or at 1:400 (for
HER-2 and HER-4) and applied for 16h at 41C. The reaction was
visualised using the EnVision Detection Kit (Dako Cytomation)
using diaminobenzidine tetrahydrochloride as the enzyme
substrate. All sections were counterstained with GM haematoxylin
stain solution (Muto Pure Chemicals, Tokyo, Japan). For negative
controls, isotype control immunoglobulin G (IgG) was used.
The staining results for HER-2 expression were scored in
accordance with the Hercep Test guidelines (Dako Cytomation):
score 0, negative, no staining or staining, but without a
membranous pattern; score 1, negative, incomplete membranous
staining or complete membranous staining in less than 10%
of tumour cells; score 2, positive, complete membranous staining
in 410% of tumour cells of moderate intensity; and score 3,
positive, complete membranous staining in 410% of tumour
cells of strong intensity. The staining results for EGFR and
HER-4 expression, in which positive staining is defined as
any staining of tumour cell membranes above background
level, whether it is complete or incomplete circumferential
staining, have been classified into three levels (þ, þþ,
and þþþ) depending on the staining intensity. Staining for
MLH1 was previously classified into three levels:   (positive in
o25% of tumour cells), þ (positive in 25–75% of tumour cells)
or as þþ (positive in 475% of tumour cells) (Kanaya et al,
2005). For analysis of the relationship with clinicopathological
characteristics, the expression of HER-2 was classified into
two levels, namely, low (score 0 or 1) and high (score 2 or 3),
whereas that of EGFR/HER-4 or MLH1 was also classified into
two levels, namely, low (  or þ) and high (þþor þþþ)o r
low (  or þ) and high (þþ), respectively. Stained sections
were evaluated by two observers with no previous knowledge of
the clinicopathological parameters. The average staining score was
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scoring between observers.
Chromogenic in situ hybridisation
Chromogenic in situ hybridisation (CISH) for HER-2 amplification
was carried out in patients with high HER-2 expression using
a ZytoDot SPEC HER-2 Probe kit (ZytoVision, Bremerhaven,
Germany) in accordance with the manufacturer’s guidelines, and
performed manually. The sections were evaluated with the
Olympus BX51 microscope (Olympus Optical Company Ltd.,
Tokyo, Japan) using a  40 dry objective. A nonamplified gene
copy number was defined as 1–5 signals per nucleus. Amplifica-
tion was defined as six or more signals per nucleus in more than
50% of cancer cells, or when a large gene copy cluster was seen.
Cell lines and cultures
Human endometrial cancer cells (HEC1A and Ishikawa) were
obtained from ATCC (Manassas, VA, USA). Human endometrial
epithelial immortalised cells (EM-E6/E7/TERT) were previously
established by us (Kyo et al, 2003). EM-E6/E7/TERT cells with
inactive AKT were established as follows: First, the mutant AKT
cDNA expressing the dominant-negative form of AKT was excised
from vector pUSEamp-Akt1(K179) (Millipore, Billerrica, MA,
USA) and subcloned into the retroviral vector pCMSCVpuro,
which was then stably transfected into EM-E6/E7/TERT cells,
generating EM-E6/E7/TERT/DN-AKT cells. Cells were maintained
in Dulbecco’s modified Eagle’s medium supplemented with 10%
fetal bovine serum and 1% penicillin/streptomycin in an atmo-
sphere of 5% CO2 at 371C.
Knockdown study of human epidermal growth factor
receptor-2
Cells were seeded and transfected with 30nM of negative control
short interfering RNA (siRNA) or human HER-2 siRNA oligo-
nucleotides (Applied Biosystems, Foster City, CA, USA) using
HiPerFect Transfection Reagent (Qiagen) according to the
manufacturer’s protocol.
Chemosensitivity assay
A total of 4 10
3 cells (Ishikawa and EM-E6/E7/TERT) or 8 10
3
cells (HEC1A) were seeded in 96-well plates, incubated with siRNA
to target HER-2 for 48h and then treated with 10nM paclitaxel
(Bristol Pharmaceuticals, Bristol, UK) for different time periods.
After each incubation, 1mg of WST-1 reagent (Roche, Mannheim,
Germany) was added to each well, and the cells were further
incubated for 2h at 371C. Absorbance at wavelengths between
420 and 480nm was then measured with a microplate reader and
WST-1 activity was determined to evaluate chemosensitivity.
The experiments were conducted in triplicate.
Western blot analysis
Whole-cell extracts were prepared as described previously
(Mizumoto et al, 2007; Mori et al, 2007) and 50mg of extracts
was then electrophoresed through a sodium dodecylsulphate–
polyacrylamide gel and transferred to a polyvinylidene difluoride
membrane. Membranes were blocked with TBS-T (150mM NaCl,
20mM Tris-HCl (pH 7.5) and 0.1% Tween 20) containing 5%
nonfat dried milk, and were then incubated with a specific primary
antibody against HER-2 (No. 2242; Cell Signaling Technology), or
with phosphorylated AKT (p-AKT) (No. 4058; Cell Signaling
Technology), AKT (No. 9272; Cell Signaling Technology) or
FOXO3a (No. 9467; Cell Signaling Technology), followed by
incubation with horseradish peroxidase-linked anti-rabbit IgG.
Immunoreactive bands were visualised using the ECL detection
system (GE Amersham Bioscience, Freiburg, Germany), according
to the manufacturer’s instructions. As an internal control for equal
protein loading, b-actin expression was examined simultaneously
using a specific antibody (sc-1615; Santa Cruz Biotechnology,
Santa Cruz, CA, USA). Relative amounts of each protein were
quantified using NIH Image software.
Statistical analysis
Statistical analysis was performed using the statistical package
StatView version 5.0 (Abacus Concepts, Berkeley, CA, USA). In the
in vivo study, we used the w
2-test for 2 2 tables to compare
the categorical data. Survival curves were computed using the
Kaplan–Meier method, whereas the log-rank test was used to
assess statistical significance. Cox’s proportional hazards regres-
sion model in a stepwise manner was used to analyse the
independent prognostic factors. For in vitro results, all values
represent mean±s.d. Statistical significance between two groups
was determined using a two-tailed t-test. A P-value o0.05 was
considered to indicate statistical significance.
RESULTS
Expression of epidermal growth factor receptor family
members and correlation with clinicopathological and
genetic characteristics in endometrial cancer
We first investigated the expression of EGFR family members
EGFR, HER-2 and HER-4 by immunohistochemistry using 63
surgical specimens of endometrioid-type endometrial cancers, on
the basis of the known finding that HER-3 expression is not
upregulated in endometrial cancer (Ejskjaer et al, 2007). The
expression of HER-2 was classified into two levels, namely, low
(score 0 or 1) and high (score 2 or 3), whereas that of EGFR/HER-4
was also classified into two levels, namely, low (  or þ) and high
(þþor þþþ). High expressions of EGFR, HER-2 and HER-4
were observed in 25 (39.7%) of 63, 26 (41.3%) of 63 and 31 (49.2%)
of 63 tumours, in which 48.0% (12 out of 25), 61.5% (16 out of 26)
and 54.8% (17 out of 31), respectively, exhibited heterogeneous
expression within tumours. There was no preferential expression
of these members in any of the specific tumour regions, such as
in the invasive front or at the centre of tumours or in areas
of squamous differentiation. Representative staining patterns of
HER-2 are shown in Figure 1. Human epidermal growth factor
receptor-2 gene amplification was further analysed in 26 patients
with a high HER-2 expression by CISH, and two patients (FIGO1b,
G1 and FIGO3c, G2, respectively) with score 3 HER-2 expression
were found to have HER-2 gene amplification. We next examined
the relationship between these expression patterns and the clinico-
pathological characteristics of the specimens (Table 1). However,
no statistically significant correlation was observed between them.
We then examined the correlation of these expression patterns
and the mutation status of PTEN, PIK3CA and KRAS, on the basis
of our previous data of the frequency of such mutations in an
overlapped population of endometrial cancers (Table 2). Among
the 45 patients from whom DNA samples were available, 18 (40%)
had a PTEN mutation, 7 (15.6%) had a PIK3CA mutation and 10
(22.2%) had a KRAS mutation. No correlation was observed
between the positivity of these factors and the mutation of each
gene. However, a high HER-2 expression was likely to have wild-
type PTEN (P¼0.079). Notably, strong HER-2 expression with a
score of 3 was significantly associated with wild-type PTEN
(P¼0.032) (Table 3).
We further examined the correlation of expression of EGFR
family members with MLH1, a representative mismatch repair
protein, loss of expression of which correlates with mutation of
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significant association was observed between them, but there was a
tendency for high HER-2 expression to be associated with high
MLH1 expression, although the difference did not reach statistical
significance (P¼0.0746) (Table 4).
Survival impact of epidermal growth factor receptor family
expression in endometrial cancer
Next, the survival impact of EGFR family member expression was
examined by Kaplan–Meier analysis (Figure 2). The median
follow-up for all patients was 5.16 years (range, 0.58–11.08 years).
Among the 63 patients, 11 patients (17.5%) had relapses of
endometrial cancer at the time of last follow-up and 12 patients
(19.0%) died. When HER-2 staining scores were used as cutoff
points to stratify patients into two groups (see Materials and
Methods), the progression-free survival (PFS) for low (score 0 or 1)
and high (score 2 or 3) HER-2 expression was 91.9 and 69.2%,
respectively (P¼0.016). The overall survival (OS) for low and high
HER-2 expression was 89.2 and 69.2%, respectively (P¼0.044).
Thus, high HER-2 expression was a factor that negatively
influenced PFS and OS rates by univariate analysis. Epidermal
growth factor receptor and HER-4 expression levels were not
factors that affected PFS or OS by univariate analysis (Supple-
mentary Figure 1). When other known variables for prognosis of
endometrial cancer, including FIGO stage, pathological grade and
myometrial invasion, were included in a Cox proportional hazard
analysis for relapse-free survival, HER-2 expression (hazard ratio
5.31, P¼0.0180) and FIGO stage were identified as independent
predictive factors of patient survival (Table 5).
The phosphatidylinositol 3-kinase–AKT pathway may be
a downstream target of human epidermal growth factor
receptor-2 in endometrial cancer
The above findings indicate that HER-2 expression is a critical
prognostic factor in endometrial cancer. We next sought to
identify the downstream target of HER-2 expression using various
endometrial cancer cell lines or immortalised endometrial
epithelial cells (EM-E6/E7/TERT). One possible candidate for a
downstream target of HER-2 was the PI3K–AKT pathway, based
on previous analyses in other tumour types (Knuefermann et al,
2003; Qi et al, 2009); hence, we focused on this pathway. To
examine the linkage between HER-2 and the PI3K–AKT pathway,
a knockdown of HER-2 was performed in the endometrial cancer
cell line Ishikawa, using siRNA techniques, and the expression of
p-AKT was evaluated by western blot analysis. As shown in
Figure 3, knockdown of HER-2 was confirmed to be efficient, with
a more than 50% reduction in expression. Notably, p-AKT
expression concomitantly decreased with HER-2 knockdown. This
finding was not limited to Ishikawa cells, as both endometrial
cancer HEC1A cells and EM-E6/E7/TERT cells exhibited a similar
decrease in p-AKT expression on HER-2 knockdown (Figure 3).
Figure 1 Immunohistochemistry of HER-2 in endometrioid-type endometrial cancer. Representative results of each score are shown (A: score 0;
B: score 1; C: score 2 ( 200) and D: score 3 ( 400)). The definition of each score is described in Materials and Methods. A breast cancer specimen (E)
with HER-2 expression was used as the positive control for appropriate staining conditions ( 400). (F) CISH analysis of the case (D) showing high levels of
HER-2 amplification ( 400). Brown dots show the large gene copy clusters.
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in endometrial cancer cells.
We examined the status of mutation in PTEN, PIK3CA and
KRAS genes in these cell lines by DNA sequencing, and found a
frameshift mutation in exon 8 of the PTEN gene (319ACTT del,
289A del) in Ishikawa cells and missense mutations in exon 20 of
the PIK3CA gene (G3145C), as well as in exon 1 of the KRAS gene
(G35A) in HEC1A cells as previously reported (Kim et al, 2004;
Oda et al, 2005). We found no mutation of these genes in EM-E6/
E7/TERT cells. These findings indicate that the linkage of HER-2
with the PI3K–AKT pathway is maintained irrespective of the
mutation status of such genes.
Table 1 Expressions of EGFR family and clinicopathological characteristics of the patients with endometrial cancer
EGFR HER-2 HER-4
Variables High Low P-value High Low P-value High Low P-value
Age (years)
o45 (n¼7) 2 5 0.5239 1 6 0.1240 3 4 0.7215
X45 (n¼56) 23 33 25 31 28 28
FIGO stage
I( n¼46) 18 28 0.8829 18 28 0.5705 24 22 0.4383
II–IV (n¼17) 7 10 8 9 7 10
Lymph-node metastasis
Negative (n¼58) 24 34 0.3485 25 33 0.3140 28 30 0.6149
Positive (n¼5 ) 14 14 32
Depth (myometrial invasion)
a, b (n¼47) 16 31 0.1168 17 30 0.1588 22 25 0.5141
c( n¼1 6 ) 97 97 97
Histopathological degree of differentiation
Grades 1 and 2 (n¼48) 17 31 0.2157 20 28 0.9089 22 26 0.3381
Grade 3 (n¼1 5 ) 87 69 96
Menopause
Peri, pre (n¼23) 6 17 0.0944 6 17 0.0634 10 13 0.4904
Post (n¼40) 19 21 20 20 21 19
Body mass index
o25 (n¼38) 17 21 0.3120 18 20 0.2254 22 16 0.0890
X25 (n¼25) 8 17 8 17 9 16
Abbreviations: EGFR¼epidermal growth factor receptor; FIGO¼International Federation of Gynaecology and Obstetrics.
Table 2 Expressions of EGFR family and genetic mutations of the
patients with endometrial cancer
PTEN
(n¼45)
PIK3CA
(n¼45)
KRAS
(n¼45)
MT
(n¼18)
WT
(n¼27)
MT
(n¼7)
WT
(n¼38)
MT
(n¼10)
WT
(n¼35)
EGFR expression
Low (n¼26) 10 16 6 20 7 19
High (n¼19) 8 11 1 18 3 16
P-value 0.8053 0.1034 0.3749
HER-2 expression
Low (n¼28) 14 14 5 23 7 21
High (n¼17) 4 13 2 15 3 14
P-value 0.0789 0.5846 0.5651
HER-4 expression
Low (n¼28) 11 17 6 22 7 21
High (n¼17) 7 10 1 16 3 14
P-value 0.9001 0.1630 0.5651
Abbreviations: EGFR¼epidermal growth factor receptor; HER-2¼human epidermal
growth factor receptor-2; MT¼mutation; WT¼wild type.
Table 3 Expression of HER-2 and PTEN mutation of the patients with
endometrial cancer
PTEN (n¼45)
HER-2 expression Mutation Wild type
Score
08 1 1
16 3
24 7
30 6
P-value 0.0799
Abbreviation: HER-2¼human epidermal growth factor receptor-2.
Table 4 Expressions of EGFR family and MLH1 of the patients with
endometrial cancer
EGFR (n¼39) HER-2 (n¼39) HER-4 (n¼39)
MLH1 expression Low High Low High Low High
Low (n¼30) 16 14 20 10 18 12
High (n¼9) 7 2 10 6 7 2
Total 23 16 23 16 25 14
P-value 0.1910 0.0746 0.3295
Abbreviations: EGFR¼epidermal growth factor receptor; HER-2¼human epidermal
growth factor receptor-2.
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is involved in paclitaxel sensitivity in endometrial
cancer cells by regulation of the phosphatidylinositol
3-kinase –AKT pathway
There is accumulating evidence that the PI3K–AKT pathway is
critically involved in drug resistance to chemotherapies of various
types of cancers by activation of survival signals. Linkage of HER-2
to p-AKT expression prompted us to examine the involvement of
HER-2 expression in the chemosensitivity of endometrial cancer
cells. We therefore sought to test the sensitivity to paclitaxel, a key
drug for endometrial cancer cells. First, preparatory experiments
were conducted to test the efficacy of paclitaxel against Ishikawa,
HEC1A and immortalised endometrial epithelial cells, in which
cells were treated with 1–1000nM of paclitaxel and cell viability
was measured by WST-1 assay. We found that 10 or 100nM was
an ideal concentration to elicit specific effects of paclitaxel in each
cell type examined (data not shown). On the basis of these
findings, all three cell lines were treated with or without HER-2
siRNA and exposed to 10nM of paclitaxel for 48h. Cell viability
was then examined by WST-1 assay. As shown in Figures 4 and 5A,
HER-2 knockdown significantly augmented the cytotoxic effect of
paclitaxel in each cell type.
Next, we monitored the expression of p-AKT during treatment
with paclitaxel in each cell type by western blot analysis. In
Ishikawa cells, p-AKT expression increased on stimulation of
paclitaxel at 24–48h after treatment (Figure 6A). We also
confirmed the expression of FOXO3a, a known downstream target
of p-AKT. FOXO3a expression began to increase at 48h and this
upregulation lasted until at least 96h (data not shown). Thus, we
confirmed the functional activation of AKT during treatment with
paclitaxel. We also tested whether HER-2 expression affects the
induction of p-AKT. Ishikawa cells were treated with 10nM
paclitaxel under knockdown of HER-2, and p-AKT expression
was then monitored. Figure 6 shows that cells with HER-2
knockdown led to decreased levels of p-AKT expression,
concomitant with increased sensitivity to paclitaxel, as shown in
Figure 4. In HEC1A cells, p-AKT expression increased on
stimulation with paclitaxel at 12h after treatment (Figure 6B),
and HER-2 knockdown led to a significant decrease in p-AKT
expression. The levels of p-AKT at 24 or 48h were unstable, but
apparently decreased on HER-2 knockdown at 48h as well. In EM-
E6/E7/TERT cells, p-AKT expression also increased on stimulation
with paclitaxel at 12h or later after treatment (Figure 6C), and
HER-2 knockdown cancelled this elevation at 48h. Thus, HER-2
knockdown inhibited paclitaxel-induced activation of p-AKT
expression in endometrial cancer or immortalised cell lines.
Interestingly, in HEC1A cells, HER-2 knockdown at 48h after
treatment, when p-AKT induction was no longer observed,
enhanced the sensitivity to paclitaxel (Figure 4B), indicating that
the basal levels of p-AKT expression have certain roles in
inhibiting the cytotoxic effect of paclitaxel.
We further sought to confirm whether the increased sensitivity
to paclitaxel by knockdown of HER-2 is primarily because of the
suppression of p-AKT expression. We prepared another immorta-
lised cell in which EM-E6E7/TERT cells were stably transfected
with the dominant-negative form of the AKT gene (EM-E6/E7/
TERT/DN-AKT cells) (see Materials and Methods), so that they
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Figure 2 Kaplan–Meier survival curves of 63 patients with endometrial
cancer in relation to HER-2 expression. (A) Relapse-free survival (B)
Overall survival.
Table 5 Cox regression hazard model for relapse-free survival
Variable Risk factor
Univariate (Kaplan-Meier) log-rank
test (P-value)
Multivariate (Cox regression model)
hazard ratio (95% confidence interval) P-value
FIGO stage XII o0.0001 6.131 (1.525–24.643) 0.0106
Grade 3 0.0042 3.576 (0.978–13.073) 0.0540
Myometrial invasion X1/2 0.0008 2.138 (0.578–7.909) 0.2548
HER-2 expression High 0.0161 5.308 (1.332–21.156) 0.0180
Abbreviations: FIGO¼International Federation of Gynaecology and Obstetrics; HER-2¼human epidermal growth factor receptor-2.
Ishikawa
HER-2
p-AKT
AKT
-Actin
HER-2 HER-2 NC NC NC siRNA HER-2
E6/E7/TERT HEC1A
Figure 3 Linkage between HER-2 and p-AKT expressions in endo-
metrial cancer or immortalised cells. Endometrial cancer Ishikawa and HEC1A
cells or endometrial immortalised EM-E6/E7/TERT cells were treated with
or without siRNA against HER-2. After 48h, cell lysates were prepared and
western blot analyses were performed with antibodies against HER-2,
p-AKT and total AKT. NC: negative control sample treated with
scrambled siRNA.
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shave inactivated AKT function. Using these cells, we performed the
paclitaxel sensitivity test by the WST-1 assay. As shown in
Figure 5B, introduction of dominant-negative AKT largely
cancelled the enhanced sensitivity to paclitaxel achieved by the
knockdown of HER-2. Thus, the effect of HER-2 seems to be
primarily dependent on AKT activity. Taken together, we conclude
that HER-2 expression has a critical role in the induction of p-AKT
expression, thereby affecting the sensitivity of endometrial cancer
cells to paclitaxel.
DISCUSSION
In this study, we found frequent expressions of EGFR, HER-2 and
HER-4 approximately in 40–50% of endometrioid-type endome-
trial cancer. There was no significant association between
expressions of these three factors and the clinicopathological
characteristics of endometrial cancer. These findings are in
contrast to a previous study by Morrison et al (2006), in which
HER-2 expression was associated with high-grade cancers (G3 and
nonendometrioid types) or with higher stages (FIGO stages IIIa–
IVb). This discrepancy may at least partly be accounted for by the
difference in sample population between the studies. Our study
examined endometrioid-type cancers, whereas Morrison et al (2006)
investigated a much larger percentage (39%) of type 2 cancers.
Nevertheless, we unexpectedly found that EGFR family expres-
sion was not closely associated with the clinicopathological
characteristics of endometrioid-type endometrial cancer in
Japanese patients. The rate of HER-2 amplification in our study
was low, with only 2 of 26 high-expression patients having HER-2
amplification. This is in accordance with Morrison’s report that
endometrioid-type cancers have low frequency of HER-2 amplifi-
cation (1% in G1, 3% in G2 and 8% in G3 cancers) (Morrison et al,
2006). Owing to the small number of samples with HER-2
amplification, its relationship with clinicopathological charac-
teristics remains unclear.
The association between the EGFR family and other genetic
alterations involved in endometrial carcinogenesis was our
next point of focus. We tested the association between mutations
of three genes representative of common genetic mutations
in endometrial cancers: PETN, PIK3CA and KRAS. Among the
factors examined, there was a tendency for HER-2 expression to
be associated with wild-type PTEN (P¼0.079). In particular,
strong HER-2 expression was closely linked to wild-type PTEN
(P¼0.032). These findings suggest that HER-2 signalling is
distinct from the PTEN mutation pathway. In the present siRNA
knockdown study, we found that HER-2 expression was closely
associated with p-AKT expression, indicating that HER-2 signal-
ling may be upstream of the PI3K–AKT pathway. These findings
suggest that HER-2 signalling activates the PI3K–AKT pathway in
a PTEN-independent manner. This scenario is easily understood,
as the PTEN mutation may not be required to activate the
PI3K–AKT pathway if an HER-2/PI3K–AKT axis exists. Another
interesting finding was the tendency for HER-2 expression to
be associated with intact MLH1 expression (P¼0.0746). We
previously showed that low MLH1 expression is mainly caused by
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sits promoter inactivation through DNA hypermethylation, which
triggers an accumulation of mutations of several genes, including
PTEN (Kanaya et al, 2005). Thus, the possible association between
HER-2 and intact MLH1 may also account for HER-2 signalling
being able to directly activate the AKT pathway, thereby not
requiring mismatch repair deficiency.
Although the in vitro knockdown study of HER-2 showed clear
association with p-AKT (Figure 3), HER-2 expression in vivo was
not significantly associated with the expression of p-AKT on the
basis of immunohistochemistry (P¼0.9411, data not shown).
However, this in vivo result is not anomalous because, in clinically
advanced cancers, there are undoubtedly several factors or
signalling pathways that regulate p-AKT expression other than
the PI3K–AKT pathway. Therefore, the possible linkage
between two factors observed in a knockdown study is not always
proven by immunohistochemical comparison with clinical cancer
samples.
Among the EFGR family, only HER-2 expression is an
independent prognostic factor in endometrial cancer. Morrison
et al (2006) studied larger numbers of patients with a broad
spectrum of histological type, grade and stage of endometrial
carcinoma, and showed that in univariate analyses, both HER-2
expression and amplification correlated with disease-specific and
progression-free survival. In multivariate analyses, HER-2 expres-
sion with amplification correlated with overall survival, but not
expression without amplification. Overall survival was significantly
shorter in patients who overexpressed and/or showed amplifica-
tion of HER-2 compared with those who did not (Morrison et al,
2006). Our data support the findings of Morrison et al (2006) and
clearly show that it is HER-2 among the EGFR family that
significantly affects patient survival.
Growth factor receptor-mediated signal transduction and PI3K–
AKT activation have been implicated in conferring resistance to
conventional chemotherapy in breast cancer cells (Yu et al, 1996;
Knuefermann et al, 2003). In uterine cancer cells (Gagnon et al,
2004, 2008) and ovarian cancer cells (Cao et al, 2008; Weng et al,
2009), the AKT pathway is known to have critical roles in
chemoresistance. The linkage of HER-2 and p-AKT expression by
our siRNA knockdown experiment indicates that HER-2 may be
involved in the chemosensitivity of endometrial cancer cells. As
expected, HER-2 inhibition by siRNA efficiently showed increased
sensitivity to paclitaxel, concomitant with p-AKT inhibition. This
increased sensitivity seemed to be at least partly p-AKT dependent,
because the increased sensitivity to paclitaxel by HER-2 knock-
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sdown was cancelled in cells with inactive AKT (Figure 5B). Thus,
it seems that HER-2 regulates the sensitivity to paclitaxel
by modulating AKT activity in endometrial cancer cells.
Knuefermann et al (2003) reported that, in MCF7 breast cancer
cells, overexpression of HER-2 caused a PI3K-dependent activation
of AKT, and was associated with an increased resistance of cells to
multiple chemotherapeutic agents. They also found that selective
inhibition of PI3K or AKT activity sensitised MCF7 breast cancer
cells to the induction of apoptosis by chemotherapeutic agents.
Our results are consistent with their study and show that HER-2 is
one of the key regulators of paclitaxel sensitivity, as an upstream
factor of AKT, in endometrial cancer.
In summary, we have shown that, among the EGFR family
members, only HER-2 is an independent prognostic factor of
endometrioid-type endometrial cancer, which may link to the
PI3K–AKT pathway, independent of PTEN mutation or mismatch
repair deficiency. Our in vitro study underscores the importance of
the HER-2/PI3K–AKT signalling pathway for regulating the
efficacy of paclitaxel in endometrial cancer cells. Therefore,
we propose the potential clinical benefit of an appropriate
combination of conventional chemotherapeutic drugs with a new
generation of signal-transduction inhibitors that target the HER-2/
PI3K–AKT pathway for the treatment of endometrial cancer.
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